1353384-61-8
Chemical Structure
AQ-101
- CAS No.: 1353384-61-8
- Formula:C16H10ClNO5
- Molecular Weight:331.71
IUPAC Name: 2-chloro-N-(4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)acetamide
InChIKey: FVBACBMWEZTDOY-UHFFFAOYSA-N
SMILES: O=C1C=2C=CC=C(O)C2C(=O)C3=C(O)C=C(C=C13)NC(=O)CCl
Biological Activity: AQ-101 is a MDM2 degrader. Upon binding to MDM2, it blocks the MDM2-MDM4 interaction, inducing autoubiquitination and proteasome-mediated degradation of MDM2. AQ-101 activates p53, upregulates downstream targets including p21 and PUMA, and induces apoptosis and cell cycle arrest in tumor cells. AQ-101 inhibits the progression of acute lymphoblastic leukemia in xenograft animal models. AQ-101 can be used for research related to acute lymphoblastic leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AQ-101 | AQ-101 is a MDM2 degrader. Upon binding to MDM2, it blocks the MDM2-MDM4 interaction, inducing autoubiquitination and proteasome-mediated degradation of MDM2. AQ-101 activates p53, upregulates downstream targets including p21 and PUMA, and induces apoptosis and cell cycle arrest in tumor cells. AQ-101 inhibits the progression of acute lymphoblastic leukemia in xenograft animal models. AQ-101 can be used for research related to acute lymphoblastic leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gu L, et al. Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice. Molecular cancer therapeutics. 2018 Feb;17(2):497-507.
- [2]. Draganov AB, et al. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs. Bioorganic & medicinal chemistry. 2019 Sep 01;27(17):3860-3865. [Content Brief]
